To use all functions of this page, please activate cookies in your browser.
With an accout for my.chemeurope.com you can always see everything at a glance – and you can configure your own website and individual newsletter.
- My watch list
- My saved searches
- My saved topics
- My newsletter
Phaseolamin, also known as "Phase 2", is a proteinaceous inhibitor of alpha-amylase. Originally isolated from white kidney beans, the protein is now commercially produced and sold as a diet aid. It works by inhibiting the action of starch degradation enzyme alpha-amylase, so that less sugar is absorbed in the small intestine. It is only active on alpha-amylases of animal origin, and does not affect those produced by plants, bacteria or fungi.
Additional recommended knowledge
Clinical trial results
In a clinical trial performed by Jay Udani, MD (Assistant Clinical Professor at the UCLA School of Medicine), a randomly selected group of obese subjects were given 1500 mg Phaseolamin twice daily with meals. Over the period of the eight week trial, which 27 subjects completed, the group using Phaseolamin showed an average weight loss of 3.79 pounds, compared with an average of 1.65 pounds for subjects taking a placebo. No adverse effects were observed during the trial.
|This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article "Phaseolamin". A list of authors is available in Wikipedia.|